These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33747147)

  • 1. Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
    Gutiérrez Calderón V; Cantero González A; Gálvez Carvajal L; Aguilar Lizarralde Y; Rueda Domínguez A
    Ther Adv Med Oncol; 2021; 13():1758835920984061. PubMed ID: 33747147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response.
    Olmos M; Glajzer J; Büntemeyer TO; Frohwitter G; Ries J; Eckstein M; Hecht M; Lutz R; Kesting MR; Weber M
    Front Oncol; 2021; 11():720951. PubMed ID: 34368002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision medicine in head and neck cancer.
    Kaidar-Person O; Gil Z; Billan S
    Drug Resist Updat; 2018 Sep; 40():13-16. PubMed ID: 30466712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.
    Shen P; Qiao B; Jin N; Wang S
    Invest New Drugs; 2022 Dec; 40(6):1282-1289. PubMed ID: 35972629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
    Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers.
    Meci A; Goyal N; Slonimsky G
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC.
    Stafford M; Kaczmar J
    Cancers Head Neck; 2020; 5():4. PubMed ID: 32195008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
    Shibata H; Saito S; Uppaluri R
    Front Oncol; 2021; 11():727433. PubMed ID: 34552878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
    Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Immunotherapy into Multimodal Treatment of Head and Neck Cancer.
    Rao YJ; Goodman JF; Haroun F; Bauman JE
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immuno-oncology of head and neck tumors].
    Kasper S; Hussain T; Virchow I; Stuschke M; Lang S
    HNO; 2019 Mar; 67(3):221-235. PubMed ID: 30635676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICO Phase II clinical trial - focus on an emerging immunotherapy strategy for the adjuvant treatment of locally-advanced oral cancers.
    Brooker RC; Schache AG; Sacco JJ
    Br J Oral Maxillofac Surg; 2021 Oct; 59(8):959-962. PubMed ID: 34325944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
    Kao HF; Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.